livagen: the Khavinson liver-targeted peptide and what the literature shows

livagen is a synthetic tetrapeptide of lysine, glutamic acid, aspartic acid, and alanine (Lys-Glu-Asp-Ala, abbreviated KEDA), developed by Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation and Gerontology. it is the liver-targeted member of the short Khavinson peptide family and was designed to represent the active fragment of a larger hepatic peptide extract. western randomized controlled trial data for livagen are minimal, and this page treats the gap honestly.

what is livagen?

livagen is a four-amino-acid synthetic peptide and one of several short tissue-targeted analogs created by the Khavinson program. the parent program isolated complex peptide preparations from animal organs and then built short synthetic analogs designed to represent the proposed active fragments.

the Khavinson program goes back to the late Soviet era at the Military Medical Academy in Leningrad, where researchers extracted what they called cytomedin peptide complexes from animal tissues. one of these complexes, derived from liver tissue, served as the basis for the short synthetic analog that became known as livagen, with the sequence Lys-Glu-Asp-Ala [1]. within the family, each short peptide is given a tissue framing: epitalon for pineal, pinealon for brain, vesugen for vasculature, thymalin for thymus, and livagen for liver. the underlying mechanistic story is shared across the class.

how is livagen supposed to work?

the Khavinson hypothesis is that short peptides cross the cell membrane, reach the nucleus, and modulate chromatin and gene expression in a tissue-selective way. this is supported by cell-culture and biophysical work from the originating group. in vivo pharmacokinetics in humans are not well characterized.

in cell-culture experiments, livagen has been reported to reduce heterochromatin packing in lymphocyte and hepatocyte nuclei from older donors, with a net effect on chromatin accessibility that the originating group interprets as reactivation of silenced genes [2]. biophysical work from the same program has proposed that short peptides like livagen can bind DNA in a sequence-selective way at promoter regions and modulate the transcription of selected target genes [3].

what is missing is the independent pharmacokinetic and pharmacodynamic characterization that would tell a reader how much livagen actually reaches the liver in humans after oral or injected administration, how long it persists, and what the effective concentration at the proposed target sites would be. those questions are essential for translating a cell-culture mechanism into a clinical claim and have not been answered at the level of detail Western pharmacology labs would expect.

what does the evidence actually show?

the livagen literature consists mostly of cell-culture and lymphocyte studies from the originating group, with a small number of open-label clinical reports in older adults. there are no large independent Western randomized controlled trials for any clinical outcome.

the preclinical case is the most accessible part of the file. in human peripheral blood lymphocytes from older donors, livagen exposure was reported to increase the proportion of lymphocytes showing active chromatin patterns, reduce heterochromatin clumping, and induce expression of selected genes including those associated with immune function [2]. in cultured hepatocytes from aged rats, livagen has been reported to modulate the expression of stress-response and antioxidant genes [3].

on the human side, what exists is mostly framed as "clinical observation" rather than formal RCT. reports from the Khavinson group and Russian clinical collaborators describe cohorts of older adults receiving courses of bioregulator peptides including livagen, with subjective improvements and changes in laboratory markers [4]. sample sizes are small, blinding and randomization details are often not described to Western trial standards, and no large independent Western group has replicated the clinical work. the honest summary: the human evidence base for livagen as a hepatoprotective drug is thin and would not meet Western regulatory standards for a clinical claim.

regulatory status

livagen is not approved by the FDA, the EMA, or any major Western regulator as a medicine. in Russia, the Khavinson bioregulators are registered as supplements rather than pharmaceutical drugs, which is a much lower evidentiary bar.

the Khavinson short peptides sit in an unusual regulatory space. in Russia they are sold legally under a parapharmaceutical or supplement framework, with package text describing tissue-supportive properties rather than disease claims. outside that footprint they are typically marketed as research compounds. a reader buying livagen outside Russia is buying a research-grade compound with no validated potency assay, no regulated identity testing, and no human safety dataset of the kind a Western regulator would expect for a clinical claim. the absence of FDA review means that nobody has formally evaluated whether the product on a label actually matches the molecule in the vial.

where it fits

livagen is one of several short tissue-targeted Khavinson peptides. the most informative comparisons are with its siblings in the bioregulator family, and the most useful contrast is with peptides that have robust Western RCT data.

within the Khavinson family, the closest comparisons are pinealon (brain-targeted), vesugen (vascular-targeted), thymalin (thymic), and epitalon (pineal-targeted). all share the same mechanistic story, the same parent program, and the same evidence-quality limitations: biologically plausible cell-culture work, thin Western RCT data.

the contrast with peptides that do have robust Western evidence is clarifying. tesamorelin has Phase 3 randomized trials and an FDA label. semaglutide has cardiovascular outcomes trials. livagen and its siblings live in a different evidence world, and the honest framing is that any liver-supportive or longevity claim should be read with that gap in mind. the broader picture of how peptides interact with the body is covered in our free peptides and your body module.